gp91 transfection with gp91^phoxmRNA to correct X-CGD granulocytes. Correction of X-CGD gp91^phox-deficient patient cells with gp91^phox mRNA. (A) Representative FACS dot plot analyses of granulocyte-rich apheresis product at 4 hours and 24 hours after EP treatment of gp91^phox -deficient X-CGD patient 5 × 10⁸ cells per milliliter with 400 µg of mRNA per milliliter in EP mix (treated) or no-EP (not treated) control. The panels are arranged in the same order and correspond to the same analyses as described in the figure legend for Figure 2C and show expression of gp91^phox protein and the PMA-stimulated NADPH oxidase activity (as increase in DHR fluorescence). (B) The kinetics of gp91^phox protein expression shown as percentage of gp91^phox+ cells over 120 hours in culture post-EP with 5 × 10⁸ cells per milliliter with 400 µg/mL gp91^phox mRNA (n = 3 ± SD; control = non-EP). (C) The kinetics of NADPH oxidase activity shown as percentage of DHR⁺ cells over 120 hours in culture post-EP for the same preparations as in panel B (n = 3 ± SD; control = non-EP).